Tests a defibrillator implant in heart disease patients who survived cardiac arrest
Tests a defibrillator implant in adults with heart disease after cardiac arrest.
Plain-language title generated from the registry record
Registry title: A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation
Key facts
- Where
- Copenhagen, DenmarkSee the site
Where in Denmark
- Copenhagen University Hospital, RigshospitaletCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT04576130
- Record updated
- 27 January 2025
- Original description
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.Read full original descriptionShow less
A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation Who Receive Complete Revascularization
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.
Inclusion: Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization; Age ≥18 years; LVEF >35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.
Exclusion: Previous CABG within the last 3 months before index hospitalization; Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy); Life expectancy less than 1 year or severe neurologic outcome; Unable or unwilling to give informed consent; Pregnancy.